Penumbra Stock Forecast, Price & News

-5.69 (-2.08 %)
(As of 06/18/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume502,192 shs
Average Volume381,867 shs
Market Capitalization$9.76 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive PEN News and Ratings via Email

Sign-up to receive the latest news and ratings for Penumbra and its competitors with MarketBeat's FREE daily newsletter.

Penumbra logo

About Penumbra

Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States, Europe, Canada, Australia, and internationally. The company offers aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the Penumbra JET, ACE, 3D Revascularization Device, and Penumbra ENGINE brands, as well as components and accessories; neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400, POD400, PAC400, and Penumbra SMART Coil brand names; and neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, DDC, and PX SLIM brands. It also provides neurosurgical aspiration tools for the removal of tissue and fluids under the Artemis Neuro Evacuation Device brand; immersive virtual reality and display system that displays and tracks upper-extremity rehabilitation exercises under the REAL Immersive System brand name; aspiration-based thrombectomy systems for vascular applications under the Indigo System brand; and detachable embolic coil systems for peripheral embolization under the Ruby Coil and Ruby LP brand names. In addition, the company offers microcatheter for the delivery of detachable coils and occlusion devices under the LANTERN brand; and detachable, microcatheter-deliverable occlusion devices designed primarily to occlude peripheral vessels under the POD (Penumbra Occlusion Device) brand name, as well as a complementary device for use with Ruby Coil and POD for vessel occlusion under the Packing Coil and POD Packing Coil brands. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was founded in 2004 and is headquartered in Alameda, California.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.95 out of 5 stars

Medical Sector

107th out of 2,097 stocks

Surgical & Medical Instruments Industry

11th out of 174 stocks

Analyst Opinion: 2.4Community Rank: 3.8Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Penumbra (NYSE:PEN) Frequently Asked Questions

Is Penumbra a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Penumbra in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Penumbra stock.
View analyst ratings for Penumbra
or view top-rated stocks.

What stocks does MarketBeat like better than Penumbra?

Wall Street analysts have given Penumbra a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Penumbra wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Penumbra's next earnings date?

Penumbra is scheduled to release its next quarterly earnings announcement on Monday, August 2nd 2021.
View our earnings forecast for Penumbra

How were Penumbra's earnings last quarter?

Penumbra, Inc. (NYSE:PEN) issued its earnings results on Tuesday, May, 4th. The company reported $0.27 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.09 by $0.18. The business earned $169.20 million during the quarter, compared to the consensus estimate of $152.67 million. Penumbra had a negative net margin of 0.89% and a positive trailing twelve-month return on equity of 2.69%. The firm's revenue for the quarter was up 23.2% compared to the same quarter last year.
View Penumbra's earnings history

How has Penumbra's stock been impacted by COVID-19 (Coronavirus)?

Penumbra's stock was trading at $176.86 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, PEN stock has increased by 51.3% and is now trading at $267.57.
View which stocks have been most impacted by COVID-19

What guidance has Penumbra issued on next quarter's earnings?

Penumbra updated its FY 2021 earnings guidance on Tuesday, May, 25th. The company provided earnings per share guidance of - for the period. The company issued revenue guidance of $695 million-$705 million, compared to the consensus revenue estimate of $681.51 million.

What price target have analysts set for PEN?

5 equities research analysts have issued 12 month price objectives for Penumbra's stock. Their forecasts range from $270.00 to $335.00. On average, they expect Penumbra's stock price to reach $314.50 in the next twelve months. This suggests a possible upside of 17.5% from the stock's current price.
View analysts' price targets for Penumbra
or view top-rated stocks among Wall Street analysts.

Who are Penumbra's key executives?

Penumbra's management team includes the following people:
  • Mr. Adam Elsesser, Co-Founder, Chairman, Pres & CEO (Age 59, Pay $219.03k)
  • Ms. Maggie S. Yuen, Chief Financial Officer (Age 49, Pay $519.04k)
  • Mr. Lambert Shiu, Chief Accounting Officer (Age 41, Pay $413.21k)
  • Ms. Johanna Roberts, Exec. VP, Gen. Counsel & Sec. (Age 49, Pay $441.93k)
  • Ms. Lynn Rothman, Exec. VP & Chief Bus. Officer (Age 60, Pay $528.89k)
  • Dr. Arani Bose, Co-Founder, Chief Innovator & Director (Age 59)
  • Mr. Ben Sorci, Exec. VP of Operations
  • Mr. Corey L. Teigen M.D., Chief Scientific Officer
  • Ms. Jee Hamlyn-Harris, Investor Relations Officer
  • Ms. Kathleen Kidd, Sr. VP of Quality & Compliance

What is Adam Elsesser's approval rating as Penumbra's CEO?

57 employees have rated Penumbra CEO Adam Elsesser on Glassdoor.com. Adam Elsesser has an approval rating of 88% among Penumbra's employees.

Who are some of Penumbra's key competitors?

What other stocks do shareholders of Penumbra own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Penumbra investors own include NVIDIA (NVDA), Intuitive Surgical (ISRG), AbbVie (ABBV), Tesla (TSLA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Netflix (NFLX), UnitedHealth Group (UNH), The Boeing (BA) and DexCom (DXCM).

What is Penumbra's stock symbol?

Penumbra trades on the New York Stock Exchange (NYSE) under the ticker symbol "PEN."

Who are Penumbra's major shareholders?

Penumbra's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (9.56%), Price T Rowe Associates Inc. MD (3.53%), Baillie Gifford & Co. (3.52%), Clearbridge Investments LLC (2.84%), William Blair Investment Management LLC (2.38%) and Generation Investment Management LLP (1.27%). Company insiders that own Penumbra stock include Adam Elsesser, Arani Bose, Bridget O'rourke, Coyne David, Don W Kassing, Harpreet Grewal, James Robert Pray, Johanna Roberts, Lynn Rothman, Sridhar Kosaraju and Thomas Wilder.
View institutional ownership trends for Penumbra

Which institutional investors are selling Penumbra stock?

PEN stock was sold by a variety of institutional investors in the last quarter, including William Blair Investment Management LLC, Ameriprise Financial Inc., Franklin Resources Inc., Generation Investment Management LLP, PFM Health Sciences LP, Price T Rowe Associates Inc. MD, BlackRock Inc., and Neuberger Berman Group LLC. Company insiders that have sold Penumbra company stock in the last year include Adam Elsesser, Arani Bose, Bridget O'rourke, Don W Kassing, Harpreet Grewal, James Robert Pray, Johanna Roberts, Lynn Rothman, and Thomas Wilder.
View insider buying and selling activity for Penumbra
or view top insider-selling stocks.

Which institutional investors are buying Penumbra stock?

PEN stock was purchased by a variety of institutional investors in the last quarter, including Morgan Stanley, Baillie Gifford & Co., Oak Ridge Investments LLC, Point72 Asset Management L.P., Bellevue Group AG, Citigroup Inc., Woodline Partners LP, and Northern Trust Corp.
View insider buying and selling activity for Penumbra
or or view top insider-buying stocks.

How do I buy shares of Penumbra?

Shares of PEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Penumbra's stock price today?

One share of PEN stock can currently be purchased for approximately $267.57.

How much money does Penumbra make?

Penumbra has a market capitalization of $9.76 billion and generates $560.41 million in revenue each year. The company earns $-15,700,000.00 in net income (profit) each year or $0.11 on an earnings per share basis.

How many employees does Penumbra have?

Penumbra employs 3,300 workers across the globe.

What is Penumbra's official website?

The official website for Penumbra is www.penumbrainc.com.

Where are Penumbra's headquarters?

Penumbra is headquartered at One Penumbra Place, Alameda CA, 94502.

How can I contact Penumbra?

Penumbra's mailing address is One Penumbra Place, Alameda CA, 94502. The company can be reached via phone at (510) 748-3200 or via email at [email protected]

This page was last updated on 6/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.